Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark
- 28 September 2022
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 93 (12), 1317-1321
- https://doi.org/10.1136/jnnp-2022-329607
Abstract
Objective We investigated whether clinical rebound occurred after fingolimod discontinuation in a complete population of patients with relapsing-remitting multiple sclerosis (RRMS) in Denmark. We further identified clinical and demographical factors associated with disease reactivation after fingolimod discontinuation. Methods The population comprised 992 RRMS patients treated with fingolimod for 6 months or more. We estimated annualised relapse rates (ARR) before, during and after treatment. We estimated overall ARRs and ARRs stratified by disease activity before discontinuation. We calculated the proportion of patients with a higher clinical disease activity after discontinuation than before treatment start. Finally, we analysed the association between variables at discontinuation and time to first relapse after discontinuation. Results The ARR 3 months after discontinuation (ARR=0.56; 95% CI=0.47 to 0.66) was statistically significantly lower (pConclusions Based on average ARR levels, there was no evidence of clinical rebound after fingolimod discontinuation. In total, 12.5% of patients had clinical rebound. Only 3.6%, however, had clinical rebound without disease activity before discontinuation. Disease activity before discontinuation, female sex and younger age were statistically significantly associated with a higher relapse risk after discontinuation.This publication has 18 references indexed in Scilit:
- Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysisTherapeutic Advances in Neurological Disorders, 2019
- Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 casesMultiple Sclerosis and Related Disorders, 2018
- Clinical activity after fingolimod cessation: disease reactivation or rebound?European Journal of Neurology, 2018
- Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod CessationThe Neurologist, 2018
- A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placeboMultiple Sclerosis Journal - Experimental, Translational and Clinical, 2017
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod TreatmentJAMA Neurology, 2016
- Long-term effects of fingolimod in multiple sclerosisNeurology, 2015
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010